Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC16A3 | O15427 | 14/20 | 0.40 |
| ▸ | SLC16A1 | P53985 | 14/20 | 0.40 |
| ▸ | TNFRSF1A | P19438 | 5/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10056591 | 0.73 | TNFRSF1A (0.42) | TNFRSF1A | |
| SCHEMBL701444 | 0.68 | GPR35 (0.46) | TNFRSF1A | |
| SCHEMBL10024687 | 0.66 | NR1H2 (0.41) | TNFRSF1A | |
| SCHEMBL6225634 | 0.66 | TNFRSF1A (0.43) | TNFRSF1A | |
| SCHEMBL6170009 | 0.64 | EGLN1 (0.42) | — | |
| SCHEMBL6221773 | 0.63 | HSD17B10 (0.54) | TNFRSF1A | |
| SCHEMBL7813546 | 0.62 | HDAC6 (0.41) | — | |
| SCHEMBL6170913 | 0.62 | KMO (0.48) | — | |
| SCHEMBL6223731 | 0.61 | CYP19A1 (0.40) | TNFRSF1A | |
| SCHEMBL29037530 | 0.60 | HTR6 (0.45) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090298905-A1 | Nitrogenatd trans-stilbene analogs, method for the obtention and medical applications thereof | UNIVERSIDAD DEL PAIS VASCO (ES) | 2009-12-03 | — | — | US | claimed |
| US-8097656-B2 | Nitrogenated trans-stilbene analogs, method for the obtention and medical applications thereof | Dominion Pharmakine S.L (ES) | 2012-01-17 | — | — | US | disclosed |
| US-20110060038-A1 | NITROGENATED TRANS-STILBENE ANALOGS, METHOD FOR THE OBTENTION AND MEDICAL APPLICATIONS THEREOF | DOMINION PHARMAKINE S.L. (ES) | 2011-03-10 | — | — | US | disclosed |
| US-20090298905-A1 | Nitrogenatd trans-stilbene analogs, method for the obtention and medical applications thereof | UNIVERSIDAD DEL PAIS VASCO (ES) | 2009-12-03 | — | — | US | disclosed |
| EP-1874723-A2 | NEW NITROGENATED TRANS-STILBENE ANALOGS, METHOD FOR THE OBTENTION AND MEDICAL APPLICATIONS THEREOF | Dominion Pharmakine S.L. (ES) | 2008-01-09 | — | — | EP | disclosed |
| WO-2006108864-A2 | NEW NITROGENATED TRANS-STILBENE ANALOGS, METHOD FOR THE OBTENTION AND MEDICAL APPLICATIONS THEREOF | DOMINION PHARMAKINE S.L. (ES) | 2006-10-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090298905-A1 | Nitrogenatd trans-stilbene analogs, method for the obtention and medical applications thereof | TNNI3, TNNT2, INMT | SLC16A3 2751/4885SLC16A1 2249/4885TNFRSF1A 1980/4885 |
| US-20110060038-A1 | NITROGENATED TRANS-STILBENE ANALOGS, METHOD FOR THE OBTENTION AND MEDICAL APPLICATIONS THEREOF | TNNI3, TNNT2, NOS2 | SLC16A3 2892/4885SLC16A1 2364/4885TNFRSF1A 2106/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.